Cargando…

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa

Detalles Bibliográficos
Autores principales:	Fischer, Peter U., King, Christopher L., Jacobson, Julie A., Weil, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Viewpoints
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215784/ https://www.ncbi.nlm.nih.gov/pubmed/28056015 http://dx.doi.org/10.1371/journal.pntd.0005163

Ejemplares similares

Lessons Learned from the Japanese Encephalitis Vaccine Introduction in India That Supported the Introduction of Ivermectin–Diethylcarbamazine–Albendazole for Lymphatic Filariasis Elimination
por: Ghosh, Raj Shankar, et al.
Publicado: (2022)

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
por: Opoku, Nicholas O., et al.
Publicado: (2023)

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India
por: Jambulingam, Purushothaman, et al.
Publicado: (2021)

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial
por: Laman, Moses, et al.
Publicado: (2022)

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis
por: Chhonker, Yashpal S., et al.
Publicado: (2023)

An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
por: Supali, Taniawati, et al.
Publicado: (2021)

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis
por: Jambulingam, Purushothaman, et al.
Publicado: (2022)

Accelerating the Uptake of WHO Recommendations for Mass Drug Administration Using Ivermectin, Diethylcarbamazine, and Albendazole
por: King, Jonathan D., et al.
Publicado: (2022)

Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
por: Khaemba, Christabel, et al.
Publicado: (2021)

Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial
por: Bjerum, Catherine M, et al.
Publicado: (2019)

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India
por: Sabesan, S., et al.
Publicado: (2022)

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial
por: Tavul, Livingstone, et al.
Publicado: (2022)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
por: Weil, Gary J, et al.
Publicado: (2020)

The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso
por: Nikièma, Achille S., et al.
Publicado: (2021)

The Impact of Repeated Rounds of Mass Drug Administration with Diethylcarbamazine Plus Albendazole on Bancroftian Filariasis in Papua New Guinea
por: Weil, Gary J., et al.
Publicado: (2008)

Global Elimination of Lymphatic Filariasis: A “Mass Uprising of Compassion”
por: Addiss, David G.
Publicado: (2013)

Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study
por: Dubray, Christine L., et al.
Publicado: (2020)

Sustaining Progress towards NTD Elimination: An Opportunity to Leverage Lymphatic Filariasis Elimination Programs to Interrupt Transmission of Soil-Transmitted Helminths
por: Means, Arianna Rubin, et al.
Publicado: (2016)

The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: A cluster randomised trial
por: Hardy, Myra, et al.
Publicado: (2020)

Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis
por: Makunde, William H, et al.
Publicado: (2003)

Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis
por: Jacobson, Julie
Publicado: (2022)

Comparison of Repeated Doses of Ivermectin Versus Ivermectin Plus Albendazole for the Treatment of Onchocerciasis: A Randomized, Open-label, Clinical Trial
por: Batsa Debrah, Linda, et al.
Publicado: (2020)

Lymphatic Filariasis Control in Tanzania: Effect of Repeated Mass Drug Administration with Ivermectin and Albendazole on Infection and Transmission
por: Simonsen, Paul E., et al.
Publicado: (2010)

Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
por: Dolo, Housseini, et al.
Publicado: (2020)

Fifteen years of programme implementation for the elimination of Lymphatic Filariasis in Ghana: Impact of MDA on immunoparasitological indicators
por: Biritwum, Nana-Kwadwo, et al.
Publicado: (2017)

Rethinking the serological threshold for onchocerciasis elimination
por: Gass, Katherine M.
Publicado: (2018)

Lymphatic filariasis control in Tanzania: effect of six rounds of mass drug administration with ivermectin and albendazole on infection and transmission
por: Simonsen, Paul E, et al.
Publicado: (2013)

Correction: Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania
por: Kroidl, Inge, et al.
Publicado: (2016)

Alternative approaches to lymphoedema care in lymphatic filariasis
por: Krishnasastry, Suma, et al.
Publicado: (2021)

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
por: Edi, Constant, et al.
Publicado: (2019)

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis
por: Macfarlane, Cara L, et al.
Publicado: (2019)

Lymphatic filariasis elimination programme in Assam, India, needs change in mass drug administration strategy to target the focus of infection
por: Khan, Abdul Mabood
Publicado: (2018)

The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji
por: Kimura, Eisaku
Publicado: (2011)

Eliminating Lymphatic Filariasis, Onchocerciasis, and Schistosomiasis from the Americas: Breaking a Historical Legacy of Slavery
por: Lammie, Patrick J., et al.
Publicado: (2007)

Modeling the Impact and Costs of Semiannual Mass Drug Administration for Accelerated Elimination of Lymphatic Filariasis
por: Stolk, Wilma A., et al.
Publicado: (2013)

Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned
por: Tripathi, Bhupendra, et al.
Publicado: (2022)

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis
por: Weil, Gary J., et al.
Publicado: (2022)

Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives
por: Wan Sulaiman, Wan Aliaa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ul96t9gsjirna5hramaejj4jnp